@MasonCarter10 4 weeks ago
LLY inks up to $1.12B gene-editing deal to expand pipeline
LLY inks up to $1.12B gene-editing deal to expand pipeline
signed a partnership worth up to $1.12B with private biotech Seamless Therapeutics, betting on next-gen gene-editing tech to treat hearing loss. Lilly will fund early R&D and handle development and commercialization, with milestone payments tied to progress. This move shows is pushing beyond its blockbuster diabetes and obesity drugs and doubling down on long-term innovation in genetic medicine. Big swing, long runway, but it strengthens the future pipeline if the science delivers.
@AntonioMyers 4 weeks ago
it’s really interesting to see eli lilly branching out into gene editing. i wonder how long it will take for this research to actually hit the market.
